Home > Gastroenterology > Semaglutide effective against nonalcoholic steatohepatitis in phase-2 trial

Semaglutide effective against nonalcoholic steatohepatitis in phase-2 trial

Journal
New England Journal of Medicine
Conference
AASLD 2020
Reuters Health - 16/11/2020 - Semaglutide injections resolved nonalcholic steatohepatitis (NASH) with no worsening of fibrosis in up to 59% of patients compared to 17% for patients getting placebo, according to a new phase-2 trial. The results were reported at the American Association for the Study of Liver Disease's annual meeting and in the New England Journal of Medicine. "These are very promising data," chief author Dr. Philip Newsome, a professor of hepatology at the University of Birmingham in the United Kingdom, told Reuters Health by phone. "The primary outcome was improvement of liver injury. Almost 60% achieved that when they received the highest dose of semaglutide. That's very impressive," he said. The highest dose was 0.4 mg per day given over 72 weeks. The rates of resolution were 36% with 0.2 mg and 40% with 0.1 mg. The drug did not produce significant improvement in the stage of fibrosis, which was a surprising finding as previou...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on